Background Oesophageal Doppler monitoring (ODM) is used clinically to optimize cardiac output (CO) and guide fluid therapy. Despite limited experimental evidence, it is assumed that increasing CO increases visceral microvascular blood flow (MBF). We used contrast-enhanced ultrasound (CEUS) to assess whether ODM-guided optimization of CO altered MBF. Methods Sixteen healthy male volunteers (62 AE 3Á4 years) were studied. Baseline measurements of CO were recorded via ODM. Hepatic and renal MBF was assessed via CEUS. Saline 0Á9% was administered to optimize CO according to a standard protocol and repeat CEUS performed. Time-intensity curves were constructed, allowing organ perfusion calculation via time to 5% perfusion (TT5). MBF was assessed via organ perfusion rise time (RT) (5-95%). Results CO increased (4535 AE 241 ml/min versus 5442 AE 329 ml/min, P<0Á0001) following fluid administration, whilst time to renal (22Á48 AE 1Á19 s versus 20Á79 AE 1Á31 s; P = 0Á03), but not hepatic (28Á13 AE 4Á48 s versus 26Á83 AE 1Á53 s; P = 0Á15) perfusion decreased. Time to renal perfusion was related to CO (renal: r = À0Á43, P = 0Á01). Hepatic nor renal RT altered following fluid administration (renal: 9Á03 AE 0Á86 versus 8Á93 AE 0Á85 s P = 0Á86; hepatic: 27Á86 AE 1Á60 s versus 30Á71 AE 2Á19 s, P = 0Á13). No relationship was observed between changes in CO and MBF in either organ (renal: r = À0Á17, P = 0Á54; hepatic: r = À0Á07, P = 0Á80). Conclusions ODM-optimized CO reduces time to renal perfusion but does not alter renal or hepatic MBF. A lack of relationship between microvascular visceral perfusion and CO following ODM-guided optimization may explain the absence of improved clinical outcome with ODM monitoring.
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MBF was assessed via organ perfusion rise time (RT) (5-95%).
Results CO increased (4535 AE 241 ml/min versus 5442 AE 329 ml/min, P<0Á0001) following fluid administration, whilst time to renal (22Á48 AE 1Á19 s versus 20Á79 AE 1Á31 s; P = 0Á03), but not hepatic (28Á13 AE 4Á48 s versus 26Á83 AE 1Á53 s; P = 0Á15) perfusion decreased. Time to renal perfusion was related to CO (renal: r = À0Á43, P = 0Á01). Hepatic nor renal RT altered following fluid administration (renal: 9Á03 AE 0Á86 versus 8Á93 AE 0Á85 s P = 0Á86; hepatic: 27Á86 AE 1Á60 s versus 30Á71 AE 2Á19 s, P = 0Á13). No relationship was observed between changes in CO and MBF in either organ (renal: r = À0Á17, P = 0Á54; hepatic: r = À0Á07, P = 0Á80). Conclusions ODM-optimized CO reduces time to renal perfusion but does not alter renal or hepatic MBF. A lack of relationship between microvascular visceral perfusion and CO following ODM-guided optimization may explain the absence of improved clinical outcome with ODM monitoring.
Background
The ability to measure cardiovascular performance is integral to anaesthetic and critical care practice. Traditional clinical monitoring modalities such as blood pressure (BP), heart rate (HR) and central venous pressure fail to provide a continuous, accurate assessment of microvascular haemodynamic performance or identify instances of tissue hypoperfusion (Wo et al., 1993; Hamilton-Davies et al., 1997) with uncorrected tissue hypoperfusion increasing surgical morbidity and mortality (Mythen & Webb, 1994) .
Alternative monitoring techniques provide estimates of stroke volume (SV) in an attempt to guide fluid and vasoactive drug therapy and optimize tissue perfusion. Traditional measurement of SV involved insertion of a pulmonary artery flotation catheter (PAFC) and measurement via thermodilution techniques. PAFC use has declined over the past decade, primarily due to concerns about the complications of insertion and an absence of studies demonstrating clinical benefit (Sandham et al., 2003; Harvey et al., 2005) . Consequently, less invasive techniques for measuring SV have been developed. Thermodilution, however, remains the gold standard for the assessment of SV against which new monitors are compared (Lee et al., 2011) .
The oesophageal Doppler monitor (ODM) is one such less invasive monitoring device. ODM has been validated against PAFC thermodilution techniques in a number of patient populations (Dark & Singer, 2004) . ODM has allowed a number of algorithms to be developed to guide intravenous (IV) fluid administration (Conway et al., 2002; Wakeling et al., 2005; Noblett et al., 2006; Lowe et al., 2010) . It is recommended for intra-operative use by the (National Institute for Health and Care Excellence, 2011) and has been advocated for use in awake patients CardioQ-ODM; NICE.
SV and cardiac output (CO) are intrinsically linked, with CO the product of SV and HR. Whilst ODM permits reproducible estimates of CO, it is unclear what benefits are brought to the patient by its use. Despite studies initially suggesting a reduction in morbidity and mortality with ODMguided perioperative fluid therapy (Abbas & Hill, 2008; Walsh et al., 2008) , recent randomized controlled trials and metaanalysis have questioned these conclusions (McKenny et al., 2013; Srinivasa et al., 2013) . CO monitoring provides more information than pressure-related measures, but it is limited to the assessment of changes in whole-body haemodynamics. The complexity of regulatory mechanisms that have been observed to impact upon blood flow through the abdominal organs would suggest that no simple relationship can exist between CO and visceral perfusion. This challenges the notion that clinical benefit will directly result from maximization of CO. Therefore, assessment of visceral microvascular blood flow (MBF) (e.g. in the gastrointestinal mucosa during and after abdominal surgery) may provide more relevant end points for guiding fluid therapy to reduce perioperative visceral hypoperfusion.
Contrast-enhanced ultrasound (CEUS) is an imaging modality that can provide near-real-time imaging of perfusion within viscera at a capillary level. CEUS has been validated for accurately measuring visceral blood flow against a number of proven technologies. Numerous in vitro and in vivo studies have validated the accuracy of CEUS in assessing microvascular blood flow, demonstrating close correlation with thermodilution (Herold et al., 2013) , mechanically controlled flow (Wei et al., 1998) and end-organ microvascular perfusion (Rim et al., 2001; Wei et al., 2001) .
CEUS utilizes echogenic microspheres that return a characteristic echo pattern. During CEUS, intravenous administration of a bolus of the contrast agent permits construction of timeacoustic intensity (AI) curves. From these curves, the time from bolus to 5% of peak AI (TT5) for each organ, pre-and postfluid administration and rise time (RT), defined as the time taken to rise from 5 to 95% of the peak AI (Fig. 1) , may be calculated. This technique has previously been validated as a method of tracking changes in MBF of the intra-abdominal viscera (Gauthier et al., 2011a,b) .
We hypothesized that administration of intravenous (IV) fluid to achieve ODM-guided CO optimization would reliably track visceral perfusion in both liver and kidney of a healthy individual.
Methods
The University of Nottingham Medical School Research Ethics Committee (A12012012) granted ethical approval for the study. The study was registered at clinicaltrials.gov (reference number NCT02167178) and conformed to the Declaration of Helsinki. Sixteen healthy male participants aged between 18 and 80 years were recruited using a standard demographically targeted postal invite. Participants attended for a prestudy health screening appointment, and written informed consent was obtained. Participants were excluded if they presented with BMI <20 or >30 kg m À2 , recent acute coronary syndrome, use of b-blockers, cerebrovascular disease, metabolic disease, known malignancy, clotting dysfunction, previous oesophageal surgery or oesophageal varices, history of epistaxis or known sensitivity to SonoVue TM . For subject demographics, see Table 1 .
Subject preparation
Subjects attended the University of Nottingham; Clinical, Metabolic and Molecular Physiology laboratories fasted for 12 h of food and fluids. A medically qualified doctor was present throughout the study, and subjects were continuously Figure 1 Example time-intensity curve for the liver. Dotted lines show 5 and 95% of the maximum values. In this example, the 5% value is 0Á037 arbitrary units (AU), occurring at 18Á41 s (TT5). The 95% value is 0Á699 AU, occurring at 32Á83 s, resulting in a rise time of 14Á42 s. 
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monitored with pulse oximetry (SpO 2 ), electrocardiogram (ECG) and non-invasive blood pressure (NIBP). A 20-G intravenous cannula was sited in the right antebrachial vein and an 18G in the left. Venous blood was drawn for measurement of haemoglobin concentration (Hb) and haematocrit (Hct). A trans-oesophageal Doppler probe (Deltex Medical, Chichester, UK) was inserted into the oesophagus via the nostril, following local anaesthesia to the nasopharynx with 10% lidocaine spray and 2% lidocaine gel (CliniMed Ltd, High Wycombe, United Kingdom). The probe was connected to a CardioQ oesophageal Doppler monitor (ODM) (Deltex Medical), and probe position was corrected to achieve an optimal Doppler flow signal. ODM placement was well tolerated by all subjects.
Contrast agent
SonoVue TM (Bracco SpA, Milan, Italy), an established contrast agent for quantitative CEUS (Mitchell et al., 2013) , was used, with preparation as per the manufacturer's instruction (Summary of product characteristics). In brief, 25 mg of lyophilized powder was reconstituted with 5 ml of 0Á9% sodium chloride solution (NaCl) in an SF 6 atmosphere.
Ultrasound settings
A Philips iU22 ultrasound machine (Philips Healthcare, Reigate, UK) with a C5-1 MHz curvilinear probe (Philips Healthcare) was used for all examinations, using dual-contrast/tissue side-by-side mode. Cine recordings were made at 9 Hz with a contrast resolution of C40, a working mechanical index (MI) of 0Á04, a maximum depth of 16 cm and focus at 8-14 cm. Gain was optimized for each subject.
Experimental protocol
Patients were placed in a semirecumbent position. The ultrasound probe was positioned to allow concurrent imaging of the liver and right kidney with probe position manipulated to optimize visualized liver and renal parenchyma. Following optimization, the probe position was marked with ink to facilitate repeat visceral imaging.
Once the probe was positioned and marked baseline recordings of SpO 2 , ECG, mean arterial blood pressure (MAP), HR and SV were made. CEUS was then performed by administering a rapid bolus of 0Á5 ml of SonoVue TM via the 20-G cannula, immediately followed by a rapid flush of 5 ml of 0Á9% NaCl. At the same time, a continuous, real-time low-MI ultrasound recording of the liver and kidney commenced and continued for 2 min. After each 2-min cycle, a 5-min pause was observed, to allow elimination of microbubbles. During which time SpO 2 , MAP, SV and HR were again measured. This sequence was repeated three times.
Subjects were then given a 250 ml bolus of 0Á9% NaCl solution as rapidly as possible via the 18-G cannula with a 50-ml syringe and three-way tap used to facilitate rapid infusion of an accurate fluid volume. On completion of this bolus, SV, HR, NIBP and SpO 2 were recorded. Repeat fluid boluses were administered, and observations were made until the SV no longer increased by >10%, at which point the SV was deemed optimal (Lowe et al., 2010) . Median fluid administration to optimize SV was 1000 ml (IQR 1000-1000 ml, range 1000-2000 ml). Immediately after optimization of SV, a further set of CEUS recordings and cardiovascular observations were performed, using the protocol outlined above. A further blood sample was then taken for measurements of haemoglobin (Hb) and haematocrit (Hct). Patients were monitored for 30 min following completion of the study protocol (Fig. 2) .
Image processing
Ultrasound video files were analysed using QLAB TM software (Philips Healthcare). Regions of interest (ROIs) were defined within liver and kidney images to allow computation of the mean pixel intensity within each ROI for each frame of the ultrasound loop (Fig. 3) . The ROI was chosen to ensure as large an area as possible was available for analysis, whilst avoiding tissue close to the capsule of each organ to minimize the effect of the subtle movement of these organs seen with respiration. Large hilar blood vessels were excluded from the ROI to achieve preferential assessment of microvascular haemodynamics.
Image analysis
For each bolus injection, ROI AI was calculated for liver and kidney from each frame (i.e. at 9 Hz) and subsequently standardized to that organs' maximum intensity. Standardized AI traces were smoothed and low-pass filtered by calculation of a 3-s moving average. The resultant time-intensity trace was used to measure RT (time from 5 to 95% of peak AI) and TT5 (time from bolus to 5% of peak AI) for each organ preand postfluid administration. Results were averaged across the three cycles recorded at each time point.
Cardiovascular parameter analysis
Data for SV, MAP, HR, Hb, Hct and SpO 2 were recorded as described above and data stored on an Excel spreadsheet (Microsoft Corporation, Redmond, WA, USA). Mean values for each of these variables before and after SV optimization were recorded.
Statistics
Sample size calculations required n = 16 (for a = 0Á05, b = 0Á85), to detect a 30% change in hepatic microvascular blood flow, results we have been able to achieve for previous work looking at similar physiological systems. Statistical analysis was performed using GraphPad Prism TM v6Á0 (La Jolla, CA, USA). Distribution of data was tested using KolmogorovSmirnov tests, with normal data expressed as mean AE standard error of the mean (SEM) and non-normal data as median AE interquartile range. Independent t-tests were applied to normal data and Mann-Whitney U-tests to nonnormal data. Categorical values were compared using Fisher's test. P<0Á05 was considered significant.
Results
CO and SpO 2 increased significantly following fluid administration (4535 AE 241 versus 5442 AE 329 ml . min À1 , P<0Á0001; 96Á9 AE 0Á4% versus 97Á8 AE 0Á3%, P<0Á01, respectively), whilst Hb and Hct decreased (149 AE 2Á5 versus 138Á5 AE 2Á8 g l À1 , P<0Á01; 0Á44 AE 0Á01 versus 0Á41 AE 0Á01, P<0Á01, respectively). MAP and HR remained unchanged following fluid administration (105Á3 AE 2Á4 versus 106Á3 AE 2Á8 mmHg, P = 0Á31; 61Á8 AE 1Á8 versus 62Á1 AE 1Á9 bpm, P = 0Á54, respectively).
Despite increases in CO and decreases in Hct following fluid administration, MBF was not altered by fluid administration in either the hepatic (RT: 27Á86 AE 1Á60 versus 30Á71 AE 2Á19 s, P = 0Á13) or renal (RT: 9Á03 AE 0Á86 versus 8Á93 AE 0Á85 s, P = 0Á86) circulation. Likewise, no relationship was observed between CO and MBF in either the kidney (r = À0Á17, P = 0Á54) or liver (r = À0Á07, P = 0Á8) (Fig. 4) .
Time to renal perfusion decreased following fluid administration (TT5: 22Á48 AE 1Á19 versus 20Á79 AE 1Á31 s, P = 0Á03), whilst time to hepatic perfusion was unaltered (TT5: 28Á13 AE 4Á48 versus 26Á83 AE 1Á53 s, P = 0Á15.). Similarly, time to renal, but not hepatic perfusion, was correlated with CO (renal: r = À0Á43, P = 0Á01; hepatic: r = À0Á21, P = 0Á26) (Fig. 4) .
There was no significant relationship observed between change in cardiac output (D CO) and change in renal rise time (D renal RT) (r = À0Á17 and P = 0Á27). A significant correlation was observed between D CO and change in renal TT5 (D TT5) (r = À0Á50, P = 0Á05; Fig. 5 ).
In the hepatic circulation, D CO did not correlate with change in hepatic rise time (D hepatic RT) (r = 0Á07, P = 0Á40), nor with change in hepatic TT5 (D hepatic TT5) (r = 0Á09, P = 0Á36).
Discussion
In this study, we use the novel technologies of CEUS and ODM to explore the relationship between CO and MBF. As expected, fluid administration reliably increased CO, reduced time to renal perfusion and reduced haematocrit. Despite these changes in macrocirculatory variables, CO showed no significant correlation with measures of MBF in either renal or hepatic circulations.
The relationship between venous filling and SV is relatively simple and is described by the Frank-Starling law; essentially, higher filling pressures lead to greater preload, and hence more forceful contraction of myocardial fibres, resulting in a greater SV and thus CO (Patterson & Starling, 1914 ) (other afterload mediated effects remaining constant over the short period of this study). The relationship between MBF and fluid administration is more complex, with multiple factors affecting perfusion of the liver and kidney. Strong autoregulatory mechanisms exist within the kidney to maintain a constant blood flow across a range of blood pressures and volemic conditions (Giebissch & Windhager, 2012) . In this healthy volunteer study, these mechanisms are likely to have remained intact.
The autoregulatory ability of the liver is less robust; with the main determinants of hepatic perfusion being sympathetic nervous system activity, circulating catecholamines and the Figure 4 Rise time (RT, s) within the hepatic (a) and renal (b) microcirculations plotted against cardiac output (hepatic r = À0Á07, P = 0Á8; renal r = À0Á17, P = 0Á54). Time to 5% perfusion (TT5, s) within the hepatic (c) and renal (d) microcirculations plotted against cardiac output (hepatic r = À0Á21, P = 0Á26: renal r = À0Á43, P = 0Á01). interaction between the arterial and portal venous circulations (the hepatic arterial buffer response) (Takala, 1996) . In hypovolemia, large volumes of blood may be mobilized from the splanchnic circulation to preserve perfusion of the brain, heart and musculature (Gelman & Mushlin, 2004) . Hypovolemia reduces splanchnic perfusion, portal venous flow and hence hepatic blood flow, and these effects persist for some time after restoration of euvolemic (Edouard et al., 1994) . These complex interactions challenge simplistic assumptions that SV and CO are key determinants of MBF. As microvascular perfusion is vital for normal organ function and tissue healing, for example at anastomoses, this lack of response to SV optimization with intravenous fluid may help to explain why recent publications and meta-analyses have failed to show a consistent reduction in morbidity or mortality when ODMguided fluid management protocols have been used in the perioperative period (McKenny et al., 2013; Srinivasa et al., 2013) .
There are a number of limitations to this present study. Firstly, the use of healthy subjects may limit the applicability of the findings to the perioperative and critical care patient. Also in an attempt to somewhat mirror a clinical population, subjects were taken from a predominantly older male age range, which may limit the conclusions of this study to a wider clinical group. Subjects were hypovolemic after a 12-h fast, as evidenced by the increase in SV with intravenous administration of c. 1L of IV crystalloid, and this reflects modern surgical practice (Gustafsson et al., 2013) . However, the impact of anaesthesia has not been addressed in this study. Additionally, as cardiac output varies with change in subject position, it was decided that subjects should be studied in a semirecumbent position to aid subject comfort. This position corresponds to the recommended positioning for patients in the intensive care unit. Importantly, participant position was not altered between CEUS measurements, to reduce any error due to change in subject or probe positioning. However, findings may therefore not be relevant in a population in a fully recumbent position.
The absolute values of CO measured in this study by ODM are in several instances around 3L min À1 . This is lower than would be expected for a healthy male population and may relate to position and relatively increased age of the study volunteers. In addition, although ODM measurements were taken by clinicians, experienced and skilled in the use of ODM monitoring, there are undoubted limitations to the use of ODM to acquire exact discrete measures of cardiac output. Furthermore, ODM calculates the volume of blood transiting the descending aorta and employs a number of assumptions to calculate cardiac output from this, whilst by necessity excluding perfusion of head and upper limbs. Although these factors may have resulted in lower than expected numerical values for CO, the ability of the ODM to accurately determine changes in cardiac output is preserved. Efforts were made to ensure consistency of tissue imaged throughout. Despite this, absolute probe fixation is not possible and small movements, such as with respiration, induce movement artefact to CEUS measures (Tang et al., 2011) . To overcome this problem, we employed a validated time-based surrogate for tissue perfusion, the RT, which is more robust to small variations in the imaged tissue (Gauthier et al., 2011b) . This technique does provide a less comprehensive assessment of microvascular status than techniques that generate volumetric data (Gauthier et al., 2011a; Tang et al., 2011) , such as microbubble destruction replenishment (Wei et al., 1998) , but is ultimately more reliable in this cohort of subjects.
A sample size calculation was determined for the primary hypothesis of a 30% change in hepatic microvascular blood flow following fluid optimization. Despite ODM assessed fluid optimization, we found no significant change in hepatic microvascular blood flow. Of note, the study was not powered to expose a relationship between the change in CO and change in MVBF before and after fluid optimization and thus may have been underpowered for detecting such a relationship. It is important however to note that there was also no suggestion of a clear relationship between CO and RT (r = À0Á07 (hepatic), r = À0Á17 (renal)).
Conclusion
This study describes a bolus method for comparison of ODMderived CO and CEUS-derived measures of renal and hepatic perfusion in the healthy, awake subject. Our data suggest that ODM-guided fluid administration reliably increases CO and time to renal perfusion, but that such changes do not increase MBF within hepatic or renal parenchyma. This challenges the assumption that optimization of CO improves abdominal visceral perfusion. The inability of ODM-guided fluid management to increase renal and hepatic MBF may be a factor in the lack of improved clinical outcome with ODM monitoring. revising article and final approval of submitted article; AB involved in concept and design of study, data acquisition and analysis, revising article and final approval of submitted article; BEP involved in concept and design of study, data acquisition and analysis, revising article and final approval of submitted article; JNL involved in concept and design of study, data analysis, revising article and final approval of submitted article; and JPW involved in concept and design of study, data analysis, revising article and final approval of submitted article.
